Research progress of selinexor in the treatment of recurrent and refractory multiple myeloma / 中国医师杂志
Journal of Chinese Physician
; (12): 296-300, 2024.
Article
en Zh
| WPRIM
| ID: wpr-1026089
Biblioteca responsable:
WPRO
ABSTRACT
Multiple myeloma is an incurable hematological malignancy. Although the continuous development of therapeutic drugs such as proteasome inhibitors and immune modulators, as well as chimeric antigen receptor T-cell (CAR-T) therapy, has improved the prognosis in recent years, some patients are still drug-resistant, presenting as refractory and recurrent disease with limited treatment options. Selinexor, a first-in-class oral selective nuclear export protein inhibitor, binds to and inhibits nuclear export protein XPO-1 to function, leading to the accumulation of tumor suppressor proteins in the nucleus and selective apoptosis of cancer cells. It has shown controllable toxicity and good efficacy in the treatment of recurrent and refractory multiple myeloma. This article discusses the anti-tumor mechanism of selinexor, its clinical research progress, and adverse reactions.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Chinese Physician
Año:
2024
Tipo del documento:
Article